Dual Effect Combination: Phase I Study Successful

Thaum Lub Ob Hlis 18, 2026, Lilly tshaj tawm tias qhov tseem ceeb ntawm TOGETHERPS0 qhib daim ntawv qhia Phase 1b txoj kev kawm tau ua tiav cov txiaj ntsig zoo. Txoj kev tshawb no tau ntsuas qhov ua tau zoo ntawm kev sib xyaw ua ke ntawm Yiqizhumab thiab Tilpotide hauv kev kho mob ntawm nruab nrab mus rau mob hnyav plaque psoriasis nrog kev rog lossis rog (thiab tsawg kawg ib qho hnyav txog qhov teeb meem) hauv cov neeg laus kho nrog Yiqizhumab monotherapy. Tag nrho ntawm 274 cov ntsiab lus tau muab tso rau hauv qhov sib piv 1: 1 kom tau txais kev kho mob subcutaneous nrog kev kho mob monotherapy nrog Yiqizhumab lossis ua ke nrog Telopotide. Ob pawg ntawm cov neeg mob tau txais kev taw qhia txog kev noj zaub mov tsis muaj calorie thiab ua kom lub cev muaj zog. Lub hom phiaj tseem ceeb ntawm txoj kev tshawb no yog los ntsuas qhov feem ntawm cov kev kawm uas ua tiav PAS1100 ntawm lub lim tiam 36 thiab tau ntsib qhov poob phaus ntau dua lossis sib npaug li 10%. Tus neeg kawm BMI yuav tsum siab dua lossis sib npaug li 30 kg / m, lossis siab dua lossis sib npaug ntawm 27 rau<30 kg/m2, and accompanied by at least one weight related complication.

Cov txiaj ntsig kev tshawb fawb pom tau tias nyob rau lub lim tiam 36, kev sib xyaw ua ke tau ua tiav thawj qhov kawg thiab tag nrho cov ntsiab lus tseem ceeb thib ob, thiab tau zoo dua li kev kho mob monotherapy nrog Yiqizhumab hais txog kev tshem tawm ntawm daim tawv nqaij thiab kev poob phaus. Hauv Tebchaws Meskas, kwv yees li 61% ntawm cov neeg mob psoriasis yog rog lossis rog dhau nrog tsawg kawg ib qho hnyav uas cuam tshuam nrog kev sib kis, qhia txog qhov xav tau kev kho mob ntau yam uas tuaj yeem daws qhov mob hnyav.

Tirzepatide Lyophilized Hmoov

1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Txhaj tshuaj
(4) Capsules
(5) Qhov ncauj poob
(6) Txau
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Internal Code: KP-2-1/001
Tirzepatide CAS 2023788-19-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4

Peb muab Tirzepatide Lyophilized Powder, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia thiab cov ntaub ntawv khoom.

Khoom siv:https://www.bloomtechz.com/news/peptides-nqi- npe- ntawm-bloom-tech-85355837.html

Thaum Lub Ob Hlis 23, 2026, Novo Nordisk tshaj tawm tias qhov poob phaus theem kuv REDEFINE 4 txoj kev tshawb fawb ntawm CagriSema piv rau tilboptin tsis mus txog qhov kawg.

Cagr1Sema yog ib qho tshuaj sib xyaw ua ke tsim los ntawm Novo Nordisk, uas suav nrog ntev - ua yeeb yam amylin analogue Cagllintide thiab GLP-1 receptor agonist, metformin. Thaum Lub Kaum Ob Hlis 2025, qhov sib xyaw no tau tshaj tawm rau kev ua lag luam hauv Tebchaws Meskas, nrog rau cov lus qhia tau tshaj tawm tias: kom txo qhov hnyav thiab tswj qhov hnyav hauv lub sijhawm ntev raws li kev txo calorie kom tsawg thiab ua kom lub cev muaj zog, tsim nyog rau cov neeg laus uas rog rog (BMI ntau dua lossis sib npaug li 30kg / m2) lossis rog dhau (BMI Ntau dua 7 kg / ntau dua lossis sib npaug li 2) teeb meem. Nws cia siab tias FDA yuav txiav txim siab pom zoo rau daim ntawv thov kev lag luam thaum kawg ntawm 2026.

REDEFINE4 yog qhov qhib daim ntawv tshuaj ntsuam xyuas ntev li 84 lub lis piam, suav nrog 809 cov neeg mob rog nrog tsawg kawg ib qho kev rog rog. Lub hom phiaj yog los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm CagriSema (2.4mg+2.4mg) piv rau Telopotide (15mg). Qhov nruab nrab qhov hnyav ntawm tus neeg mob yog 114.2 kg. Tom qab ua tiav qhov kev tshuaj ntsuam xyuas, qhov hnyav ntawm pawg CagriSema thiab pawg tirizin poob los ntawm 23.0% thiab 25.5%, feem, tom qab 84 lub lis piam; Raws li lub hom phiaj los kho kev tsom xam, qhov poob phaus ntawm ob pawg yog 20.2% thiab 23.6%, feem, thiab txoj kev tshawb fawb kawg tsis tau mus txog qhov tsis muaj qhov tsis txaus ntseeg thawj qhov kawg.

Thaum Lub Ob Hlis 24, 2026, Pfizer thiab Xianweida Biotechnology tshaj tawm tias lawv tau mus txog qhov kev pom zoo kev lag luam kev sib koom tes ntawm cov tiam tshiab ntawm GLP-1 receptor agonist Ecn0gLutide txhaj (tom qab no hu ua Ecn0gLutide txhaj).

Raws li kev pom zoo, Pfizer yuav tau txais cov cai lag luam tshwj xeeb thiab kev txaus siab ntawm cov khoom lag luam hauv Suav teb Mainland, ua thawj kauj ruam hauv nws cov tswv yim layout nyob rau hauv lub ntiaj teb no metabolic teb nyob rau hauv Tuam Tshoj; Nyob rau tib lub sijhawm, raws li Kev Tso Cai Ua Lag Luam Kev Lag Luam (MAH) ntawm cov khoom muaj ntawv tso cai, Dahua Biotech yog lub luag haujlwm rau kev tshawb fawb thiab kev tsim kho, sau npe, tsim khoom, thiab muab cov khoom muaj ntawv tso cai. BioNTech yuav muaj cai tau txais kev them nyiaj siab tshaj plaws txog $ 495 lab los ntawm Pfizer, suav nrog kev them nqi qis, kev sau npe, thiab kev muag khoom tseem ceeb them nyiaj.

Enoglutide yog ib tiam tshiab ntawm cAMP biased GLP-1 receptor agonist ntawm nws tus kheej tsim los ntawm Xianweida Biology, uas yuav muab cov txheej txheem kho kom raug ntau dua rau cov neeg mob ntshav qab zib hom 2 thiab kev tswj qhov hnyav mus ntev. Nrog nws txoj kev tsis ncaj ncees tshwj xeeb, Kev Txhaj Tshuaj Enoglutide tau ua kom pom kev ua tau zoo thiab kev nyab xeeb hauv ntau qhov kev tshawb fawb soj ntsuam. Qhov nruab nrab qhov hnyav poob ntawm Suav cov pej xeem tom qab hloov cov placebo mus txog 15.1%, 92.8% ntawm cov neeg mob ua tiav kev kho mob hnyav, thiab ntau dua 80% ntawm cov neeg mob tau txais cov qauv ntshav qabzib (HbA1c).<7.0%). Enoglutide injection has been approved by the National Drug Administration (NMPA) to be marketed for the treatment of adult type 2 diabetes in January 2026, and its application for marketing license of adult long-term weight management indications has been accepted by NMPA.

Thaum Lub Ob Hlis 24, 2026, Saint Yin Biotechnology, lub tuam txhab kho mob theem biotechnology tau tsom mus rau kev txhim kho RNA cuam tshuam (RNAi) kho tshiab, tshaj tawm tias nws tus kheej -tsim tshuaj ntsuam xyuas SGB 9768 tau tso cai rau menyuam ntsuag los ntawm US Food and Drug Administration (FDAmbe) rau kev kho mob me me ntawm cov neeg laus. glomerulonephritis (IC-MPGN).

IC-MPGN yog ib yam kab mob tsis tshua muaj raum, feem ntau tshwm sim los ntawm kev ua kom ntau dhau ntawm cov kab ke ua ke. Lub pathogenesis ntawm tus kab mob no yog complex thiab cov chav kawm mus sai heev, thaum ib txwm kev kho mob kev xaiv yog txwv. SGB-9768 yog ib qho tshuaj sIRNA lub hom phiaj ntxiv rau C3, tam sim no nyob rau theem I kev sim tshuaj. Nws lub hom phiaj qhia muaj xws li IC.MPGN, thawj 1EA nephropathy (gAN), thiab C3 glomerupathies (C3G), ntawm lwm cov kab mob hauv lub raum ntxiv. Hauv kev sim ua tiav Phase 1, ib qho kev tswj hwm subcutaneous ntawm SGB-9768 tau ua tiav koob tshuaj-nyob ntawm thiab tseem ceeb txhua hnub txo qis hauv C3 qib thiab inhibition ntawm kev ua tiav txoj hauv kev, ua kom pom kev nyab xeeb zoo thiab ua kom ntev, thiab ua kom pom nws lub peev xwm zoo tshaj plaws hauv nws chav kawm.